NCT03626480 is a clinical trial of No treatment in Congenital Heart Disease, sponsored by Guangzhou Medical University.

Who is sponsoring NCT03626480?

NCT03626480 is sponsored by Guangzhou Medical University.

What drugs are being tested in NCT03626480?

Interventions in NCT03626480: No treatment.

What condition does NCT03626480 study?

NCT03626480 studies Congenital Heart Disease.

Is NCT03626480 still recruiting?

NCT03626480 is currently recruiting now. Last updated 11 February 2020.

Last reviewed 2020-02-11 · How we verify

NCT03626480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peri-operative Nutrition in Infants With Congenital Heart Disease

Recruiting now Last updated 11 February 2020

What this trial tests

trial testing No treatment in Congenital Heart Disease in 20,000 participants. Currently enrolling.

Timeline

9 July 2018

Primary endpoint
1 September 2028

1 September 2028

Quick facts

Lead sponsor	Guangzhou Medical University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	20,000
Start date	9 July 2018
Primary completion	1 September 2028
Estimated completion	1 September 2028
Sites	1 location across China

Drugs / interventions tested

No treatment — full drug profile →

Conditions studied

Congenital Heart Disease — all drugs for Congenital Heart Disease →

Sponsor

Guangzhou Medical University

Who can join

Adults 1 Day to 12 Months, any sex, with Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of our multi-center cohort study is to build a large platform to follow up the peri-operative nutrition of children with congenital heart disease. And data will be collected pre and 1, 3, 6, 12 months post surgery including physical, laboratory, imaging examination and questionnaire. The primary outcome is nutrition status (measured as WAZ, WHZ and HAZ) and secondary outcomes were the biochemical index and quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Using artificial intelligence to predict post-operative outcomes in congenital heart surgeries: a systematic review.
Mohammadi I, Rajai Firouzabadi S, Hosseinpour M, Akhlaghpasand M, et al · · 2024 · cited 9× · PMID 39702050 · DOI 10.1186/s12872-024-04336-6

Verify or expand the search:

Other trials of No treatment

Trials testing the same drug.

NCT07261085 — A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Me · active not recruiting
NCT05659381 — Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer · Phase 3 · recruiting
NCT05567237 — Effects of Microcurrent Treatment With and Without Resistance Exercises · NA · recruiting
NCT06150859 — Ayahuasca Assisted Psychotherapy for Grief · Phase 2 · unknown
NCT04808180 — Clinical Efficacy of Biomimetic Hydroxyapatite in the Treatment of Molar Incisor Hypomineralization. · NA · completed

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting

Other Guangzhou Medical University trials

Trials by the same sponsor.

NCT07521618 — One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation · NA · not yet recruiting
NCT07352176 — Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions · NA · not yet recruiting
NCT06462092 — Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Canc · Phase 1, PHASE2 · recruiting
NCT07461714 — AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia · active not recruiting
NCT06296745 — Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03626480 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Medical University
Last refreshed: 11 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03626480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing